Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC39H47ClN10O5S |
InChIKeyATKNMUSVVUPZFT-DTXPUJKBSA-N |
CAS Registry2853543-33-4 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | United States | 19 Oct 2022 |